File Download

Conference Paper: Efficacy and safety of dabigatran versus warfarin in patients with non-valvular atrial fibrillation

TitleEfficacy and safety of dabigatran versus warfarin in patients with non-valvular atrial fibrillation
Authors
Issue Date2015
Citation
The 2015 Annual Meeting of the British Pharmacological Society (PHARMACOLOGY 2015), Queen Elizabeth II Centre, London, UK., 15-17 December 2015. How to Cite?
AbstractDabigatran, a direct thrombin inhibitor, is the first new oral anticoagulant approved for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) as an alternative to warfarin. However, the clinical effectiveness and adverse events concerning the use of dabigatran are not well described outside clinical trial setting. The aim of this study was to compare the efficacy and safety of dabigatran and warfarin in patients with NVAF in the ...
DescriptionAbstract no. PC023
Persistent Identifierhttp://hdl.handle.net/10722/229961

 

DC FieldValueLanguage
dc.contributor.authorLau, WCY-
dc.contributor.authorChan, EW-
dc.contributor.authorWong, ICK-
dc.date.accessioned2016-08-23T14:14:20Z-
dc.date.available2016-08-23T14:14:20Z-
dc.date.issued2015-
dc.identifier.citationThe 2015 Annual Meeting of the British Pharmacological Society (PHARMACOLOGY 2015), Queen Elizabeth II Centre, London, UK., 15-17 December 2015.-
dc.identifier.urihttp://hdl.handle.net/10722/229961-
dc.descriptionAbstract no. PC023-
dc.description.abstractDabigatran, a direct thrombin inhibitor, is the first new oral anticoagulant approved for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) as an alternative to warfarin. However, the clinical effectiveness and adverse events concerning the use of dabigatran are not well described outside clinical trial setting. The aim of this study was to compare the efficacy and safety of dabigatran and warfarin in patients with NVAF in the ...-
dc.languageeng-
dc.relation.ispartofPHARMACOLOGY 2015-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleEfficacy and safety of dabigatran versus warfarin in patients with non-valvular atrial fibrillation-
dc.typeConference_Paper-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturepostprint-
dc.identifier.hkuros260124-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats